Policies

You may call the offices at any time you have questions regarding your condition, treatment, and medication. If your question is urgent, either your physician or another staff member will return your call promptly. If your problem is not urgent, your call will usually be returned within 24 to 48 hours.

Do NOT use this site to contact your physician if you are having a medical emergency.

Confidentiality

Your medical record is strictly private. We do not provide information regarding your condition to your family, doctor, or insurance company without your knowledge and consent.

Research Department

To learn more about our research department, or if you have any questions, please contact our Research Staff:

  • Stacey Rhynard – Clinical Research Coordinator, DM1
  • Karen McWhirter – Clinical Research Coordinator
  • Jackelyne Amador – Clinical Research Coordinator
  • Thania Escamilla – Clinical Research Coordinator

Phone: 702.851.4672
Fax: 702.851.4670

Clinical Trials

The Women’s Cancer Center of Nevada Foundation for Research is a member of the Gynecologic Oncology Group (GOG), a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of their processes is utilized in order to constantly improve the quality of patient care.

Below is a partial list of current clinical trials with which the Women’s Cancer Center is involved. To learn more, or to find other related studies, please visit the NIH Clinical Trials website which features a searchable database.

Las Vegas Medical Marijuana Trials

    •  – What marijuana culture is or will become has been widely discussed by many. To one small group of doctors, though, that culture means little. For these doctors, their patients are the only ones who matter.

» Learn more

GOG-264

    •  – A randomized phase II trial of Paclitaxel and carboplatin vs. bleomycin, etoposide and cisplatin for newly diagnosed advanced stage and recurrent chemo-naïve sex cordstromal tumors of the ovary.

GOG-3004

    •  – A phase III, randomized, double blind, placebo controlled, multicenter study of Olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy.

GOG-213

    •  – A phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary Cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer.

GOG-260

    •  – A phase II evaluation of Elesclomol Sodium and weekly paclitaxel in the treatment of recurrent or persistent-resistant ovarian, fallopian tube or primary peritoneal cancer.

GOG-281

    •  – A randomized phase II/III study to access the efficacy of Trametinib in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer.

GOG-283

    •  – A phase II trial of DCTD-sponsored Dasatinib in recurrent/persistent ovary, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma characterized for the retention of loss of BAF250a expression.

GOG-244

    •  – The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors, and impact in newly diagnosed patients.

GOG-258

    •  – A randomized phase II trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel for optimally debulked, advanced endometrial cancer.

GOG-275

    •  – A phase III randomized trial of pulse actinomycin-D multi-day methotrexate for the treatment of low-risk gestational trophoblastic neoplasia.

GOG-277

    •  – A phase III randomized trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for the uterus-limited, high grade uterine leiomyosarcoma.

GOG-286B

    •  – A randomized phase II/III study of paclitaxel/carboplatin/Metformin vs Paclitaxel/Carboplatin/Placebo as initial therapy for measurable stage III or IVA, Stage IVB, or recurrent endometrial cancer.

GOG-238

    •  – A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.

GOG-283

    •  – A phase II trial of DCTD-sponsored Dasatinib in recurrent/persistant ovary, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma characterized for the retention of loss of BAF250a expression.

GOG-286B

    •  – A randomized phase II/III study of paclitaxel/carboplatin/Metformin vs Paclitaxel/Carboplatin/Placebo as initial therapy for measurable stage III or IVA, Stage IVB, or recurrent endometrial cancer.

GOG-237

    •  – Comparative analysis of CA-IX, p16, proliferative markers, and human papilloma virus (HPV) in the diagnosis of significant cervical lesions in the patients with cytologic diagnosis of atypical glandular cells (AGC).

GOG-244

    •  – The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors and impact in newly diagnosed patients.

GOG-263

    •  – Randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy.

GOG-274

    •  – A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: OUTBACK Trial (ANZGOG 0902).

GOG-278

    •  – Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic LNDX) for Stage IA1 (LVSI+) and IA2-IB1 (=2cm) cervical cancer.

GOG-244/UMC 12.07.005

    •  – The lymphedema and gynecologic cancer (LEG) study: incidence, risk factors, and impact in newly diagnosed patients.

GOG-270

    •  – GROningen International Study on Sentinel nodes in vulvar cancer; An observational study.

GOG-279/UMC 13.05.008

    •  – A phase II trial evaluating cisplatin and gemcitabine concurrent with intensity-modulated radiation therapy (IMRT) in the treatment of locally advanced squamous cell carcinoma of the vulva.

PR-1205

    •  – A prospective, safety and efficacy cohort study of elevate anterior and apical prolapsed repair system compared to native tissue repair for pelvic organ prolapsed repair.

PR-1206

     – A prospective, safety and efficacy cohort study of elevate posterior and apical prolapsed repair system compared to native tissue repair for pelvic organ prolapsed repair.

Published Papers

Professionally, our doctors have authored over 80 peer-reviewed journal articles and book chapters, and in 2011 Dr Spirtos became the first American editor of Bonney’s textbook of Gynecological Surgery, which has been in publication for over 100 years.

Below is a selection of their most recent works.

Bonney’s Gynaecological Surgery, 11th Edition

    • Lopes T, Spirtos NM, Naik R, Monaghan JM.

Published February 2011, Wiley-Blackwell

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

    • DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE,

Spirtos NM

    • , Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ.

J Clin Oncol. 2014 Feb 10;32(5):458-64.

Virtual reality robotic surgical simulation: an analysis of gynecology trainees.

    • Sheth SS, Fader AN, Tergas AI,

Kushnir CL

    • , Green IC.

J Surg Educ. 2014 Jan-Feb;71(1):125-32.

The use of argon beam coagulation in treating vulvar intraepithelial neoplasia III: a retrospective review.
Kushnir CL

    • ,

Fleury AC

    • , Hill MC, Silver DF,

Spirtos NM

    • .

Gynecol Oncol. 2013 Nov;131(2):386-8.

Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration.
Kushnir CL

    • ,

Fleury AC

    • , Couch J, Hill MC,

Spirtos NM

    • .

Gynecol Oncol. 2013 Aug;130(2):350-3.

Post fellowship training in “new-to-them” surgical techniques: assessment of learning curve characteristics.

    • Miao J,

Fleury AC

    • ,

Kushnir CL

    • , Silver DF, Naik R,

Spirtos NM

    • .

Gynecol Oncol. 2011 Jun 1;121(3):620-4.

Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment.
Fleury AC

    • ,

Kushnir CL

    • , Giuntoli RL 2nd,

Spirtos NM

    • .

BJOG. 2012 Jan;119(2):202-6.

Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.

    • Giuntoli RL 2nd, Lessard-Anderson CR, Gerardi MA,

Kushnir CL

    • , Cliby WA, Metzinger DS, Gostout BS.

Int J Gynecol Cancer. 2013 Jun;23(5):869-76.

Defining the role of lymphadenectomy in gynaecological oncology.
Spirtos NM

    • .

BJOG. 2013 Mar;120(4):381-3.

Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.

    • Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K,

Spirtos NM

    • , Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL.

Gynecol Oncol. 2013 Feb;128(2):155-9.

Laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy: initial multi-institutional experience for treatment of invasive cervical cancer.

    • Boruta DM, Fagotti A, Bradford LS, Escobar PF, Scambia G,

Kushnir CL

    • , Michener CM, Fader AN.

J Minim Invasive Gynecol. 2014 May-Jun;21(3):394-8.

Perioperative care in gynecologic oncology.
Kushnir CL

    • , Díaz-Montes TP.

Curr Opin Obstet Gynecol. 2013 Feb;25(1):23-8.

Extrauterine inflammatory myofibroblastic tumor: A case report.
Kushnir CL

    • , Gerardi M, Banet N, Shih IeM, Diaz-Montes T.

Gynecol Oncol Case Rep. 2013 Jul 30;6:39-41

Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival.

    • Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV, Ueda SM,

Fleury AC

    • , Diaz-Montes TP, Bristow RE.

Int J Gynecol Cancer. 2012 Feb;22(2):273-9.

Vulvar basal cell carcinoma in a 20-year-old: Case report and review of the literature.
Fleury AC

    • , Junkins-Hopkins JM, Diaz-Montes T.

Gynecol Oncol Case Rep. 2011 Dec 2;2(1):26-7.

Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.

    • Tewari KS, Filiaci VL,

Spirtos NM

    • , Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME.

Gynecol Oncol. 2012 Apr;125(1):87-93.

Primary uterine cancer in Maryland: impact of distance on access to surgical care at high-volume hospitals.

    • Gunderson CC, Tergas AI,

Fleury AC

    • , Diaz-Montes TP, Giuntoli RL 2nd.

Int J Gynecol Cancer. 2013 Sep;23(7):1244-51.

Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.

    • Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K,

Spirtos NM

    • , Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CL.

J Clin Oncol. 2012 Nov 1;30(31):3786-91.

Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study.

    • Walker JL, Piedmonte MR,

Spirtos NM

    • , Eisenkop SM, Schlaerth JB, Mannel RS, Barakat R, Pearl ML, Sharma SK.

J Clin Oncol. 2012 Mar 1;30(7):695-700.

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

    • Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK,

Spirtos NM

    • , Fischer EG, Leslie KK.

Gynecol Oncol. 2012 Mar;124(3):569-74.

Resource Library

Finding Information Online
The Women’s Cancer Center of Nevada believes that the more informed you are, the more comfortable you will be making the decisions that best meet your health and lifestyle needs. The library contains published research and articles by our own physicians, while other sections of this website contain detailed information about our areas of specialty: laparoscopic cancer surgery, cytroreductive surgery and pelvic reconstruction and urogynecology.

Caveats

  • Searching the Internet for the information about cancer can lead to competent, well researched data that is helpful and enlightening. Unfortunately, you may also find advice that is questionable, hard to interpret, out of date-or even dangerous. The good news is that there are steps you can take to ensure that the information you gather will be reliable. We strongly recommend you read the “Getting Started” guide in our articles section.
  • Under the best of circumstances, it’s easy to get information overload in the digital age! After a recent diagnosis, or while you are undergoing treatment, you may feel particularly overwhelmed. Take things slowly, and consider letting someone else help you research. Also, be sure to discuss any questions or concerns you have with your physician.
  • The Internet is a dynamic entity, it changes all the time. We cannot guarantee that the excellent link we looked at yesterday will still be there in the morning. Your help in keeping our links “fresh” would be gratefully accepted. Just use the Contact Us page and let us know.
Resource Links

Association for Cancer Online Resources

National Ovarian Cancer Coalition

Nevada Care Connection

Ovarian Cancer National Alliance

Owareness

Website Disclaimer

The contents of the Women’s Cancer Center site are designed for informational and research purposes only and are not engaged in rendering medical advice or professional services. The information provided through the Women’s Cancer Center site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider. In a medical emergency please call 911.

Policy Modifications

The Women’s Cancer Center of Nevada reserves the right to modify this policy at any time and without notice. We recommend checking periodically to remain informed of any updates or changes.

All information provided through this site is provided without warranty of any kind.

This Web site is controlled and operated by the Women’s Cancer Center from its corporate headquarters in Las Vegas, Nevada. Any claim or dispute relating to your use or attempted use of this Web site shall be governed by and construed in accordance with the laws of the State of Nevada, without giving effect to its conflict of laws provisions.